227 related articles for article (PubMed ID: 27291296)
21. A high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytes.
Winterberg M; Kirk K
Sci Rep; 2016 Jul; 6():29241. PubMed ID: 27385291
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death.
van Schalkwyk DA; Chan XW; Misiano P; Gagliardi S; Farina C; Saliba KJ
Biochem Pharmacol; 2010 May; 79(9):1291-9. PubMed ID: 20067768
[TBL] [Abstract][Full Text] [Related]
23. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue.
Sonoiki E; Ng CL; Lee MC; Guo D; Zhang YK; Zhou Y; Alley MR; Ahyong V; Sanz LM; Lafuente-Monasterio MJ; Dong C; Schupp PG; Gut J; Legac J; Cooper RA; Gamo FJ; DeRisi J; Freund YR; Fidock DA; Rosenthal PJ
Nat Commun; 2017 Mar; 8():14574. PubMed ID: 28262680
[TBL] [Abstract][Full Text] [Related]
24. Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
Creek DJ; Charman WN; Chiu FC; Prankerd RJ; Dong Y; Vennerstrom JL; Charman SA
Antimicrob Agents Chemother; 2008 Apr; 52(4):1291-6. PubMed ID: 18268087
[TBL] [Abstract][Full Text] [Related]
25. (-)-Epigallocatechin-3-Gallate Inhibits the Chaperone Activity of Plasmodium falciparum Hsp70 Chaperones and Abrogates Their Association with Functional Partners.
Zininga T; Ramatsui L; Makhado PB; Makumire S; Achilinou I; Hoppe H; Dirr H; Shonhai A
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206141
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
27. Assessment
Yipsirimetee A; Chiewpoo P; Tripura R; Lek D; Day NPJ; Dondorp AM; Pukrittayakamee S; White NJ; Chotivanich K
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0148121. PubMed ID: 34978886
[TBL] [Abstract][Full Text] [Related]
28. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action.
Birth D; Kao WC; Hunte C
Nat Commun; 2014 Jun; 5():4029. PubMed ID: 24893593
[TBL] [Abstract][Full Text] [Related]
29. Heterologous Expression of a Novel Drug Transporter from the Malaria Parasite Alters Resistance to Quinoline Antimalarials.
Tindall SM; Vallières C; Lakhani DH; Islahudin F; Ting KN; Avery SV
Sci Rep; 2018 Feb; 8(1):2464. PubMed ID: 29410428
[TBL] [Abstract][Full Text] [Related]
30. Genomic and biological features of Plasmodium falciparum resistance against antimalarial endoperoxide N-89.
Morita M; Hayashi K; Sato A; Hiramoto A; Kaneko O; Isogawa R; Kurosaki Y; Miyoshi SI; Chang KS; Wataya Y; Kim HS
Gene; 2019 Oct; 716():144016. PubMed ID: 31377318
[TBL] [Abstract][Full Text] [Related]
31. Computational and experimental elucidation of Plasmodium falciparum phosphoethanolamine methyltransferase inhibitors: Pivotal drug target.
Singh J; Vijay S; Mansuri R; Rawal R; Kadian K; Sahoo GC; Kumar M; Sharma A
PLoS One; 2019; 14(8):e0221032. PubMed ID: 31437171
[TBL] [Abstract][Full Text] [Related]
32. Identification of Three Novel Ring Expansion Metabolites of KAE609, a New Spiroindolone Agent for the Treatment of Malaria, in Rats, Dogs, and Humans.
Huskey SE; Zhu CQ; Lin MM; Forseth RR; Gu H; Simon O; Eggimann FK; Kittelmann M; Luneau A; Vargas A; Li H; Wang L; Einolf HJ; Zhang J; Favara S; He H; Mangold JB
Drug Metab Dispos; 2016 May; 44(5):653-64. PubMed ID: 26921386
[TBL] [Abstract][Full Text] [Related]
33. A G358S mutation in the Plasmodium falciparum Na
Qiu D; Pei JV; Rosling JEO; Thathy V; Li D; Xue Y; Tanner JD; Penington JS; Aw YTV; Aw JYH; Xu G; Tripathi AK; Gnadig NF; Yeo T; Fairhurst KJ; Stokes BH; Murithi JM; Kümpornsin K; Hasemer H; Dennis ASM; Ridgway MC; Schmitt EK; Straimer J; Papenfuss AT; Lee MCS; Corry B; Sinnis P; Fidock DA; van Dooren GG; Kirk K; Lehane AM
Nat Commun; 2022 Sep; 13(1):5746. PubMed ID: 36180431
[TBL] [Abstract][Full Text] [Related]
34. Antimalarials Targeting the Malaria Parasite Cation ATPase
Zagórska A; Jaromin A
Curr Top Med Chem; 2023; 23(3):214-226. PubMed ID: 36411573
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents.
Meyers MJ; Anderson EJ; McNitt SA; Krenning TM; Singh M; Xu J; Zeng W; Qin L; Xu W; Zhao S; Qin L; Eickhoff CS; Oliva J; Campbell MA; Arnett SD; Prinsen MJ; Griggs DW; Ruminski PG; Goldberg DE; Ding K; Liu X; Tu Z; Tortorella MD; Sverdrup FM; Chen X
Bioorg Med Chem; 2015 Aug; 23(16):5144-50. PubMed ID: 25797165
[TBL] [Abstract][Full Text] [Related]
36. Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.
Stein DS; Jain JP; Kangas M; Lefèvre G; Machineni S; Griffin P; Lickliter J
Antimicrob Agents Chemother; 2015; 59(6):3493-500. PubMed ID: 25845867
[TBL] [Abstract][Full Text] [Related]
37. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
[TBL] [Abstract][Full Text] [Related]
39. Sequencing and heterologous expression in Saccharomyces cerevisiae of a Cryptococcus neoformans cDNA encoding a plasma membrane H(+)-ATPase.
Gorgojo B; Portillo F; Martínez-Suárez JV
Biochim Biophys Acta; 2000 Dec; 1509(1-2):103-10. PubMed ID: 11118522
[TBL] [Abstract][Full Text] [Related]
40. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Li R; Jain JP; Lefèvre G; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Oct; 58(10):6209-14. PubMed ID: 25114127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
